RxDoctor Payments Data

Hasan Dawood, MD

Neurology · Atlanta, GANPI 1831695329

Payments from drug & device makers

$7,242in general payments, 2019–2025

Across 310 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$615
  • Axsome Therapeutics, Inc.$373
  • MDD US Operations, LLC$312
  • Pfizer$311
  • Biogen$308
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,15499%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,242 in reported general payments places this provider in the 70th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$214,447
Medicare patients
381
Services billed
6,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab15$126,244
RexultiBrexpiprazole32$46,700
AptiomEslicarbazepine Acetate16$30,143
Nurtec OdtRimegepant Sulfate16$30,121
UbrelvyUbrogepant18$27,049
BriviactBrivaracetam15$22,307
FycompaPerampanel18$20,809
NayzilamMidazolam16$16,554
RytaryCarbidopa/Levodopa28$15,324
HorizantGabapentin Enacarbil14$11,570
QuliptaAtogepant11$8,912
Memantine Hcl108$2,138
Gabapentin140$2,015
Ziprasidone Hcl17$1,844
Levetiracetam37$1,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$289$46,70032 claims
UCB, Inc.Briviact, Nayzilam$615$38,86131 claims
AbbVieUbrelvy, Qulipta$1,311$35,96129 claims
PfizerNurtec Odt$311$30,12116 claims
Amneal Pharmaceuticals LLCRytary$86$15,32428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 506 neurology providers in Georgia.

Other neurology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →